Human C-reactive protein induces endothelial dysfunction in biobreeding diabetic rats

Ishwarlal Jialal, Harmeet Kaur, Sridevi Devaraj, Gerred Smith

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: C-reactive protein (CRP) levels in diabetes predict cardiovascular events. Also, human CRP (hCRP) exacerbated the proinflammatory, pro-oxidant and procoagulant states in a spontaneous model of type 1 diabetes mellitus (T1DM), the biobreeding (BB) rat. Since there is a paucity of data examining the role of CRP on endothelial dysfunction in animal models of diabetes, we tested this hypothesis in the diabetic BB rat. Methods: Diabetic BB rats (n = 4 per group) were injected with human serum albumin (HSA) or hCRP [hCRP = 20 mg/ kg body weight; intraperitoneal (IP)] for three consecutive days. The rats were euthanized on day 4. Biomarkers that were assayed included endothelin-1 (ET-1), soluble intracellular adhesion molecule-1 (sICAM-1), Von Willebrand factor (vWF) and 6-keto prostaglandin F1-alpha (6-keto PGF1-α) in plasma. Results: hCRP administration resulted in a significant increase in plasma levels. Furthermore, hCRP-treated rats had significantly increased circulating levels of ET-1 (1.12 ± 0.6 pg/mL versus 0.4 ± 0.21 pg/mL), vWF (45 ± 2.4 ng/mL versus 34 ± 7 ng/mL) and sICAM-1 (41 ± 3 ng/mL versus 34 ± 3.4 ng/mL) compared to HSA-treated rats (p < 0.05). There was no significant effect on 6-keto PGF1-α levels. Conclusion: Hence, in this preliminary report, we make the novel observation that hCRP induces endothelial dysfunction in a spontaneous model of T1DM, and this could have implications for the vascular complications in diabetics.

Original languageEnglish (US)
Pages (from-to)550-553
Number of pages4
JournalDiabetes and Vascular Disease Research
Volume10
Issue number6
DOIs
StatePublished - Nov 2013

Fingerprint

C-Reactive Protein
von Willebrand Factor
Endothelin-1
Type 1 Diabetes Mellitus
Serum Albumin
Diabetic Angiopathies
Reactive Oxygen Species
Animal Models
Biomarkers
Body Weight
Observation

Keywords

  • C-reactive protein
  • endothelial dysfunction
  • inflammation
  • type 1 diabetes mellitus

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Human C-reactive protein induces endothelial dysfunction in biobreeding diabetic rats. / Jialal, Ishwarlal; Kaur, Harmeet; Devaraj, Sridevi; Smith, Gerred.

In: Diabetes and Vascular Disease Research, Vol. 10, No. 6, 11.2013, p. 550-553.

Research output: Contribution to journalArticle

Jialal, Ishwarlal ; Kaur, Harmeet ; Devaraj, Sridevi ; Smith, Gerred. / Human C-reactive protein induces endothelial dysfunction in biobreeding diabetic rats. In: Diabetes and Vascular Disease Research. 2013 ; Vol. 10, No. 6. pp. 550-553.
@article{31e5981449c24b52b5b8c55f14bbdae5,
title = "Human C-reactive protein induces endothelial dysfunction in biobreeding diabetic rats",
abstract = "Objective: C-reactive protein (CRP) levels in diabetes predict cardiovascular events. Also, human CRP (hCRP) exacerbated the proinflammatory, pro-oxidant and procoagulant states in a spontaneous model of type 1 diabetes mellitus (T1DM), the biobreeding (BB) rat. Since there is a paucity of data examining the role of CRP on endothelial dysfunction in animal models of diabetes, we tested this hypothesis in the diabetic BB rat. Methods: Diabetic BB rats (n = 4 per group) were injected with human serum albumin (HSA) or hCRP [hCRP = 20 mg/ kg body weight; intraperitoneal (IP)] for three consecutive days. The rats were euthanized on day 4. Biomarkers that were assayed included endothelin-1 (ET-1), soluble intracellular adhesion molecule-1 (sICAM-1), Von Willebrand factor (vWF) and 6-keto prostaglandin F1-alpha (6-keto PGF1-α) in plasma. Results: hCRP administration resulted in a significant increase in plasma levels. Furthermore, hCRP-treated rats had significantly increased circulating levels of ET-1 (1.12 ± 0.6 pg/mL versus 0.4 ± 0.21 pg/mL), vWF (45 ± 2.4 ng/mL versus 34 ± 7 ng/mL) and sICAM-1 (41 ± 3 ng/mL versus 34 ± 3.4 ng/mL) compared to HSA-treated rats (p < 0.05). There was no significant effect on 6-keto PGF1-α levels. Conclusion: Hence, in this preliminary report, we make the novel observation that hCRP induces endothelial dysfunction in a spontaneous model of T1DM, and this could have implications for the vascular complications in diabetics.",
keywords = "C-reactive protein, endothelial dysfunction, inflammation, type 1 diabetes mellitus",
author = "Ishwarlal Jialal and Harmeet Kaur and Sridevi Devaraj and Gerred Smith",
year = "2013",
month = "11",
doi = "10.1177/1479164113503971",
language = "English (US)",
volume = "10",
pages = "550--553",
journal = "Diabetes and Vascular Disease Research",
issn = "1479-1641",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Human C-reactive protein induces endothelial dysfunction in biobreeding diabetic rats

AU - Jialal, Ishwarlal

AU - Kaur, Harmeet

AU - Devaraj, Sridevi

AU - Smith, Gerred

PY - 2013/11

Y1 - 2013/11

N2 - Objective: C-reactive protein (CRP) levels in diabetes predict cardiovascular events. Also, human CRP (hCRP) exacerbated the proinflammatory, pro-oxidant and procoagulant states in a spontaneous model of type 1 diabetes mellitus (T1DM), the biobreeding (BB) rat. Since there is a paucity of data examining the role of CRP on endothelial dysfunction in animal models of diabetes, we tested this hypothesis in the diabetic BB rat. Methods: Diabetic BB rats (n = 4 per group) were injected with human serum albumin (HSA) or hCRP [hCRP = 20 mg/ kg body weight; intraperitoneal (IP)] for three consecutive days. The rats were euthanized on day 4. Biomarkers that were assayed included endothelin-1 (ET-1), soluble intracellular adhesion molecule-1 (sICAM-1), Von Willebrand factor (vWF) and 6-keto prostaglandin F1-alpha (6-keto PGF1-α) in plasma. Results: hCRP administration resulted in a significant increase in plasma levels. Furthermore, hCRP-treated rats had significantly increased circulating levels of ET-1 (1.12 ± 0.6 pg/mL versus 0.4 ± 0.21 pg/mL), vWF (45 ± 2.4 ng/mL versus 34 ± 7 ng/mL) and sICAM-1 (41 ± 3 ng/mL versus 34 ± 3.4 ng/mL) compared to HSA-treated rats (p < 0.05). There was no significant effect on 6-keto PGF1-α levels. Conclusion: Hence, in this preliminary report, we make the novel observation that hCRP induces endothelial dysfunction in a spontaneous model of T1DM, and this could have implications for the vascular complications in diabetics.

AB - Objective: C-reactive protein (CRP) levels in diabetes predict cardiovascular events. Also, human CRP (hCRP) exacerbated the proinflammatory, pro-oxidant and procoagulant states in a spontaneous model of type 1 diabetes mellitus (T1DM), the biobreeding (BB) rat. Since there is a paucity of data examining the role of CRP on endothelial dysfunction in animal models of diabetes, we tested this hypothesis in the diabetic BB rat. Methods: Diabetic BB rats (n = 4 per group) were injected with human serum albumin (HSA) or hCRP [hCRP = 20 mg/ kg body weight; intraperitoneal (IP)] for three consecutive days. The rats were euthanized on day 4. Biomarkers that were assayed included endothelin-1 (ET-1), soluble intracellular adhesion molecule-1 (sICAM-1), Von Willebrand factor (vWF) and 6-keto prostaglandin F1-alpha (6-keto PGF1-α) in plasma. Results: hCRP administration resulted in a significant increase in plasma levels. Furthermore, hCRP-treated rats had significantly increased circulating levels of ET-1 (1.12 ± 0.6 pg/mL versus 0.4 ± 0.21 pg/mL), vWF (45 ± 2.4 ng/mL versus 34 ± 7 ng/mL) and sICAM-1 (41 ± 3 ng/mL versus 34 ± 3.4 ng/mL) compared to HSA-treated rats (p < 0.05). There was no significant effect on 6-keto PGF1-α levels. Conclusion: Hence, in this preliminary report, we make the novel observation that hCRP induces endothelial dysfunction in a spontaneous model of T1DM, and this could have implications for the vascular complications in diabetics.

KW - C-reactive protein

KW - endothelial dysfunction

KW - inflammation

KW - type 1 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84886066213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886066213&partnerID=8YFLogxK

U2 - 10.1177/1479164113503971

DO - 10.1177/1479164113503971

M3 - Article

C2 - 24028935

AN - SCOPUS:84886066213

VL - 10

SP - 550

EP - 553

JO - Diabetes and Vascular Disease Research

JF - Diabetes and Vascular Disease Research

SN - 1479-1641

IS - 6

ER -